Literature DB >> 7969239

Serial neurophysiological studies of intramuscular botulinum-A toxin in humans.

J A Hamjian1, F O Walker.   

Abstract

To characterize the time course of intramuscular botulinum toxin-induced paresis, we serially performed electrophysiological measurements and recorded the sonographic size of an extensor digitorum brevis (EDB) muscle in 10 human subjects before and after injecting the EDB with 10 units of botulinum-A toxin. All EDB CMAPs decreased within 48 h, with peak decline at day 21 (8.3 +/- 3.1 mV to 3.0 +/- 0.9 mV). Decline of mean rectified voltage during maximal voluntary contraction of the EDB paralleled the change in CMAP amplitude. Average decrements to 2-Hz repetitive stimulation never exceeded 6% (day 42) and exercise failed to facilitate significantly CMAP amplitude. Atrophy peaked at day 42. The F-wave to M-wave ratio increased at day 2; silent periods did not change. Our findings confirm a primary peripheral action of the toxin, but a superimposed, transient central effect of the drug cannot be excluded. Intramuscular injections into EDB provide a useful model for studying chemodenervation effects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7969239     DOI: 10.1002/mus.880171207

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  26 in total

1.  Functional end-plate recovery in long-term botulinum toxin therapy of hemifacial spasm: a nerve conduction study.

Authors:  C Butera; R Guerriero; S Amadio; D Ungaro; H Tesfaghebriel; F Bianchi; G Comi; U Del Carro
Journal:  Neurol Sci       Date:  2012-02-25       Impact factor: 3.307

Review 2.  Botulinum toxin for the treatment of movement disorders.

Authors:  Mary Ann Thenganatt; Stanley Fahn
Journal:  Curr Neurol Neurosci Rep       Date:  2012-08       Impact factor: 5.081

Review 3.  Neurophysiological effects of botulinum toxin type A.

Authors:  G Abbruzzese; A Berardelli
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

4.  Clinical use of non-A botulinum toxins: botulinum toxin type C and botulinum toxin type F.

Authors:  R Eleopra; V Tugnoli; R Quatrale; O Rossetto; C Montecucco; D Dressler
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

5.  Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A.

Authors:  M K Houser; G L Sheean; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-05       Impact factor: 10.154

6.  Longitudinal neurophysiological assessment of intramuscular type-A botulin toxin in healthy humans.

Authors:  L Lispi; L Leonardi; A Petrucci
Journal:  Neurol Sci       Date:  2017-11-11       Impact factor: 3.307

7.  Cosmetic use of botulinum toxin-a affects processing of emotional language.

Authors:  David A Havas; Arthur M Glenberg; Karol A Gutowski; Mark J Lucarelli; Richard J Davidson
Journal:  Psychol Sci       Date:  2010-06-14

8.  [Botulinum toxin treatment : therapy success in cases of depression and ongoing pension applications].

Authors:  A Bachhuber; G Reichel; M Doberenz; A Stenner; W Hermann
Journal:  Nervenarzt       Date:  2009-06       Impact factor: 1.214

9.  Intra-rater and inter-rater reliability of the Penn Spasm Frequency Scale in People with chronic traumatic spinal cord injury.

Authors:  Patricia B Mills; Alok P Vakil; Cassidy Phillips; Lawrence Kei; Brian K Kwon
Journal:  Spinal Cord       Date:  2018-01-25       Impact factor: 2.772

10.  Botulinum toxin type A in the treatment of patients with cervical dystonia.

Authors:  Allison Brashear
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.